Latest News

With the opportunity to treat spades of infectious diseases, cancers and single gene disorders, there is enormous potential in RNA therapeutics. To realize it, however, researchers will need to optimize delivery to on-target cells, minimize exposure to off-target cells and move beyond the liver.

Starting a TechBio company is a rewarding challenge. In this episode Yogev Debbi, Co-founder and CEO at Mana.bio enjoys discussing it with Omri Amirav-Drory from NFX, his co-founder from their first TechBio company Genome Compiler and now an investor at Mana.bio where we're disrupting Drug Delivery using ML/AI.

An agreement to embed chemical substance data from the CAS Content CollectionTM directly into the Mana.bio AI data acquisition workflow via an application programmable interface (API). This collaboration will enrich Mana.bio’s proprietary database to fuel its AI engine, with an expected 70% reduction in resources allocated to molecular data acquisition and preparation.